drugset / Trial / NCT01214122

A Drug-Drug Interaction Study Between AZD9668 and Warfarin to Study the Effect of AZD9668 on the Metabolism and Effect of Warfarin

NCT01214122

Phase 1 Withdrawn AstraZeneca
Open-labelBasic science

Summary

The primary purpose of this study is to determine whether the treatment with AZD9668 will affect the metabolism and effect of Warfarin.

Timeline

Start
2010-11
Primary completion
2010-12
Completion
2010-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Alvelestat Small molecule 60 mg Oral
Subject Warfarin Small molecule 25 mg Oral

Indications

No indication recorded.